Effects of adefovir dipivoxil on serum IFN-γ and IL-4 in patients with chronic hepatitis

JIANG Jun,CAI Xiong,MIAO Xiao-hui

DOI: https://doi.org/10.3969/j.issn.1008-1704.2006.02.006

2006-01-01

Abstract:Objective To study the dynamic changes of IFN-γ and IL-4 in the serum of patients with chronic hepatitis B (CHB) treated with adefovir dipivoxil. Methods One hundred and eight CHB patients(96 males and 12 femals) were enrolled in a randomized, double-blinded, controlled and multicentral Phase Ⅲ clinical trial of adefovir dipivoxil. At different time(before therapy, and 4 weeks, 12 weeks, 24 weeks, 48 weeks after therapy), the serum level of IFN-γ and IL-4 of each patient were determined by specific-ELISA, and the serum HBV-DNA level was also quantitated by real time fluorescent PCR. Results The serum level of ALT and AST improved significantly in CHB patient 12 weeks after therapy with adefovir dipivoxil(P<0.05), and kept normal from 24 weeks after therapy to the end point of the clinical trial. The serum HBV DNA decreased significantly in 4 weeks after therapy(P< 0.05) and continued to decrease till the end point. Meanwhile, the level of serum IFN-γ and IL-4 increased slowly till the end point, which was significantly higher in 24 weeks and 48 weeks of therapy than that of pretherapy(P<0.001). Conclusion The immunity of patients with CHB can be enhanced by adefovir dipivoxil, which may result from the reduction of viral load and restoration of CD4~+T cell reactivity.